JP2012523243A5 - - Google Patents

Download PDF

Info

Publication number
JP2012523243A5
JP2012523243A5 JP2012505149A JP2012505149A JP2012523243A5 JP 2012523243 A5 JP2012523243 A5 JP 2012523243A5 JP 2012505149 A JP2012505149 A JP 2012505149A JP 2012505149 A JP2012505149 A JP 2012505149A JP 2012523243 A5 JP2012523243 A5 JP 2012523243A5
Authority
JP
Japan
Prior art keywords
promoter
tumor
stem cell
cytotoxic protein
coding region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012505149A
Other languages
English (en)
Japanese (ja)
Other versions
JP5727458B2 (ja
JP2012523243A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/054844 external-priority patent/WO2010119039A1/en
Publication of JP2012523243A publication Critical patent/JP2012523243A/ja
Publication of JP2012523243A5 publication Critical patent/JP2012523243A5/ja
Application granted granted Critical
Publication of JP5727458B2 publication Critical patent/JP5727458B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012505149A 2009-04-13 2010-04-13 改変間葉系幹細胞及びそれを使用した腫瘍の治療方法 Active JP5727458B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16878709P 2009-04-13 2009-04-13
US61/168,787 2009-04-13
PCT/EP2010/054844 WO2010119039A1 (en) 2009-04-13 2010-04-13 Engineered mesenchymal stem cells and method of using same to treat tumors

Publications (3)

Publication Number Publication Date
JP2012523243A JP2012523243A (ja) 2012-10-04
JP2012523243A5 true JP2012523243A5 (enExample) 2013-05-23
JP5727458B2 JP5727458B2 (ja) 2015-06-03

Family

ID=42270435

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012505149A Active JP5727458B2 (ja) 2009-04-13 2010-04-13 改変間葉系幹細胞及びそれを使用した腫瘍の治療方法

Country Status (12)

Country Link
US (2) US9434925B2 (enExample)
EP (1) EP2419113B1 (enExample)
JP (1) JP5727458B2 (enExample)
KR (1) KR20120088542A (enExample)
CN (1) CN102695517B (enExample)
AU (1) AU2010237130B2 (enExample)
BR (1) BRPI1013771A2 (enExample)
CA (1) CA2758120C (enExample)
IL (1) IL215581A0 (enExample)
RU (1) RU2539099C2 (enExample)
SG (1) SG175127A1 (enExample)
WO (1) WO2010119039A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010045659A1 (en) 2008-10-17 2010-04-22 American Gene Technologies International Inc. Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
US20130171115A1 (en) * 2011-12-30 2013-07-04 Gang Li Cell-mediated gene therapy for cancer using mesenchymal stem cells expressing a suicide gene
KR102053385B1 (ko) * 2012-02-01 2019-12-06 포항공과대학교 산학협력단 12량체 trail 및 hsv-tk 자살유전자를 동시에 발현하는 벡터 및 이를 이용한 항암 줄기세포 치료제
US20130203166A1 (en) * 2012-02-06 2013-08-08 Protobios Llc Stimulation of multipotency of mesenchymal stem cells by chemokine ccl5
GB201202319D0 (en) 2012-02-10 2012-03-28 Orbsen Therapeutics Ltd Stromal stem cells
US20140065110A1 (en) 2012-08-31 2014-03-06 The Regents Of The University Of California Genetically modified msc and therapeutic methods
DK4389764T3 (da) * 2012-11-05 2026-04-13 Regeneron Pharma Genetisk modificerede gnavere og fremgangsmåder til anvendelse heraf
US10472647B2 (en) 2012-12-21 2019-11-12 The Administrators Of The Tulane Educational Fund Primary mesenchymal stem cells as a vaccine platform
WO2015100268A1 (en) * 2013-12-23 2015-07-02 The Regents Of The University Of California Mesenchymal stem cells for targeted cancer therapy
KR20160107303A (ko) * 2014-01-17 2016-09-13 웨이크 포리스트 유니버시티 헬스 사이언시즈 활성 작용제 전달의 강화 방법
US20170239297A1 (en) 2014-08-18 2017-08-24 Apceth Gmbh & Co. Kg Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
ES2841075T3 (es) * 2014-10-24 2021-07-07 Calidi Biotherapeutics Inc Enfoque de inmunoterapia de combinación para el tratamiento del cáncer
CN104622903B (zh) * 2015-01-20 2018-10-09 奥思达干细胞有限公司 抗恶性黑色素瘤的干细胞制剂及其制备方法
US10350245B2 (en) 2015-01-21 2019-07-16 Fred Hutchinson Cancer Research Center Point-of-care and/or portable platform for gene therapy
WO2016138340A1 (en) * 2015-02-27 2016-09-01 Saint Louis University Tumor suppressor sall1 as a therapeutic agent for treating cancer
US20180037868A1 (en) * 2015-02-27 2018-02-08 Apceth Gmbh & Co. Kg Genetically modified mesenchymal stem cell expressing klotho
WO2016146819A1 (en) * 2015-03-18 2016-09-22 Apceth Gmbh & Co. Kg Hypoxia-induced expression of therapeutic proteins in mesenchymal stem cells
US11980663B2 (en) 2015-07-08 2024-05-14 American Gene Technologies International Inc. HIV pre-immunization and immunotherapy
HK1248588A1 (zh) 2015-08-11 2018-10-19 Calidi Biotherapeutics, Inc. 用於癌症治疗中的天花疫苗
WO2017036925A1 (en) * 2015-08-28 2017-03-09 Apceth Gmbh & Co. Kg Mesenchymal stem cells for the treatment of metastatic liver disease
IL297238B2 (en) 2016-01-15 2024-08-01 American Gene Tech Int Inc Methods and preparations for gamma-delta T-cell activation
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
JP7153332B2 (ja) 2016-02-08 2022-10-14 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Hivワクチン接種および免疫療法
ES2911448T3 (es) 2016-03-09 2022-05-19 American Gene Tech Int Inc Vectores combinados y métodos para el tratamiento del cáncer
AU2017277499B2 (en) * 2016-06-07 2022-07-28 The Pacific Heart, lung & Blood Institute Compositions and methods for treating cancer
WO2017213697A1 (en) 2016-06-08 2017-12-14 American Gene Technologies International Inc. Non-integrating viral delivery system and methods related thereto
CA3028982A1 (en) 2016-07-08 2018-01-11 American Gene Technologies International Inc. Hiv pre-immunization and immunotherapy
WO2018017882A1 (en) 2016-07-21 2018-01-25 American Gene Technologies International Inc. Viral vectors for treating parkinson's disease
AU2017354272A1 (en) 2016-11-03 2019-05-23 Exostem Biotec Ltd. Mesenchymal stem cells populations, their products, and use thereof
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
US11820999B2 (en) 2017-04-03 2023-11-21 American Gene Technologies International Inc. Compositions and methods for treating phenylketonuria
KR20190141695A (ko) 2017-04-13 2019-12-24 센티 바이오사이언시스, 인코포레이티드 병용 암 면역요법
US12559769B2 (en) 2017-06-16 2026-02-24 American Gene Technologies International Inc. Methods and compositions for the activation of tumor cytotoxicity via human gamma-delta t-cells
WO2019195142A1 (en) 2018-04-03 2019-10-10 The Board Of Trustees Of The Leland Stanford Junior University Mesenchymal stem cells comprising a chimeric antigen receptor (car) for treating inflammatory and autoimmune diseases
KR102662837B1 (ko) 2018-06-04 2024-05-03 카리디 바이오테라퓨틱스, 인크. 바이러스 치료법의 강화를 위한 세포-기반 비히클
EP3806864A4 (en) * 2018-06-14 2022-05-25 Loma Linda University GENETIC HEMATOPOIETIC STEM CELLS FOR THE TREATMENT OF ACUTE MYELOIC LEUKEMIA
CA3116138A1 (en) 2018-10-17 2020-04-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
EP3876952A4 (en) 2018-11-05 2022-08-24 American Gene Technologies International Inc. VECTOR SYSTEM FOR EXPRESSING REGULATORY RNA
CA3116192C (en) 2018-11-06 2025-09-23 Calidi Biotherapeutics (Nevada), Inc. IMPROVED SYSTEMS FOR CELL-MEDIATED ONCOLYTIC VIRAL THERAPY
US20220241337A1 (en) * 2019-02-22 2022-08-04 The Trustees Of Columbia University In The City Of Newyork Preparing tissues for delivery of therapeutic and diagnostic agents and delivering the agents
SG10201902002SA (en) * 2019-03-06 2020-10-29 Nat Univ Singapore Non-viral modification of mesenchymal stem cells
EP4556072A3 (en) * 2019-08-23 2025-06-11 Orbsen Therapeutics Limited Compositions for monocyte and macrophage polarization and methods of use
EP3995130A1 (en) 2020-11-06 2022-05-11 JunctuCell Biomed Manufacturing GmbH A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections
US20230414730A1 (en) 2020-11-06 2023-12-28 Aatec Medical Gmbh A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6265564B1 (en) * 1996-08-02 2001-07-24 Regeneron Pharmaceuticals, Inc. Expressed ligand-vascular intercellular signalling molecule
US7098185B2 (en) * 1998-05-18 2006-08-29 University College London Polypeptide hormone phosphatonin
WO2001091802A1 (en) * 2000-05-30 2001-12-06 Baylor College Of Medicine Chimeric viral vectors for gene therapy
WO2002069953A1 (en) * 2001-03-01 2002-09-12 The Board Of Regents Of The University Of Texas System Methods of treating lung inflammation
US20030165579A1 (en) * 2002-02-27 2003-09-04 Chih-Hui Lin Euphorbia antiquorum extract, a pharmaceutical composition containing the same and methods for treatment of cancers
EP1544213B1 (en) * 2003-12-19 2008-02-20 Charité - Universitätsmedizin Berlin Use of ligands of the antigen cd52 for the treatment of solid tumours and bone-related cancerous diseases
JP2006194752A (ja) * 2005-01-14 2006-07-27 Sumitomo Metal Mining Co Ltd X線回折測定における試料固定方法および試料固定具
KR101022401B1 (ko) * 2005-09-29 2011-03-15 아주대학교산학협력단 자살유전자를 발현하는 중간엽 줄기세포를 포함하는 암치료용 조성물
ES2507507T3 (es) 2007-05-24 2014-10-15 Apceth Gmbh & Co. Kg Células madre mesenquimales CD34 negativas modificadas genéticamente para el tratamiento de tumores

Similar Documents

Publication Publication Date Title
RU2011146048A (ru) Сконструированные мезенхимальные стволовые клетки и способ их применения для лечения опухолей
Shi et al. Engineered mesenchymal stem/stromal cells against cancer
Howells et al. Oncolytic viruses—interaction of virus and tumor cells in the battle to eliminate cancer
Deng et al. Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9
Power et al. Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer
Yin et al. Modulation of the intratumoral immune landscape by oncolytic herpes simplex virus virotherapy
JP2008056679A5 (enExample)
JP2024045608A (ja) 制御性rnaを発現させるためのベクターシステム
EP4378487A3 (en) Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
Xiao et al. Oncolytic viruses: advanced strategies in cancer therapy
JP2012010710A5 (enExample)
CA2640528A1 (en) Oncolytic adenoviruses for cancer treatment
Feng et al. Stabilization of G-quadruplex DNA and inhibition of Bcl-2 expression by a pyridostatin analog
Cao et al. Gene therapy for hepatocellular carcinoma based on tumour-selective suicide gene expression using the alpha-fetoprotein (AFP) enhancer and a housekeeping gene promoter
Patil et al. Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients
Bilsland et al. Virotherapy: cancer gene therapy at last?
Lucas et al. Hexon modification to improve the activity of oncolytic adenovirus vectors against neoplastic and stromal cells in pancreatic cancer
JP2015506697A (ja) 12量体trail及びhsv−tk自殺遺伝子を同時に発現するベクター並びにそれを用いた抗癌幹細胞治療剤
CN101565718A (zh) 三靶向嵌合型溶瘤腺病毒Ad5/F11载体的构建方法及其应用
JP2013530965A5 (enExample)
Shen et al. Specific CEA-producing colorectal carcinoma cell killing with recombinant adenoviral vector containing cytosine deaminase gene
Yoon et al. A vesicular stomatitis virus glycoprotein epitope-incorporated oncolytic adenovirus overcomes CAR-dependency and shows markedly enhanced cancer cell killing and suppression of tumor growth
WO2022107705A1 (ja) 新規遺伝子組換えワクシニアウイルス及びその利用
Tagawa et al. Cancer therapy with local oncolysis and topical cytokine secretion
Asavarut et al. Chimeric adeno-associated virus and bacteriophage: a potential targeted gene therapy vector for malignant glioma